Stratatech Corporation:企業の製品パイプライン分析2014

◆英語タイトル:Stratatech Corporation - Product Pipeline Analysis, 2014 Update
◆発行会社/調査会社:GlobalData
◆商品コード:GDME13426PD
◆発行日:2014年7月
◆調査対象地域:アメリカ
◆産業分野:医療機器
◆ページ数:31
◆レポート言語:英語
◆レポート形式:PDF
◆納品方式:Eメール
◆販売価格オプション(消費税別)
Single UserUSD750 ⇒換算¥84,750見積依頼/購入/質問フォーム
Site Price(同一国内共有可)USD1,500 ⇒換算¥169,500見積依頼/購入/質問フォーム
Enterprise Price(複数国内共有可)USD2,250 ⇒換算¥254,250見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の市場調査資料のご購入、委託調査サービスに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

★グローバルリサーチ資料[Stratatech Corporation:企業の製品パイプライン分析2014]についてメールでお問い合わせはこちら
*** レポート概要(サマリー)***

Summary

Stratatech Corporation (Stratatech) is a regenerative medicine company. The company offers proprietary skin substitute products for therapeutic and research uses. Its products include stratagraft and expressgraft. Stratatech’s stratagraft is a temporary wound cover, which promotes wound healing by the patient’s own cells. The company’s expressgraft is an enhanced tissue that produces various levels of natural wound healing and antimicrobial factors. It offers human tissue substitutes generated with NIKS keratinocytes and cells derived from them for biological therapies. The company offers models for high throughput genotoxicity testing and cancer drug screening. It markets its products through brands. Stratatech is headquartered in Madison, Wisconsin, the US.

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:

- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Stratatech Corporation
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.

Reasons to Buy:

- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio

*** レポート目次(コンテンツ)***

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Stratatech Corporation Company Snapshot 5
Stratatech Corporation Company Overview 5
Key Information 5
Stratatech Corporation Pipeline Products and Clinical Trials Overview 6
Stratatech Corporation – Pipeline Analysis Overview 8
Key Facts 8
Stratatech Corporation – Major Products and Services 9
Stratatech Corporation Pipeline Products by Development Stage 10
Stratatech Corporation Clinical Trials by Trial Status 12
Stratatech Corporation Pipeline Products Overview 14
EpiReady 14
EpiReady Product Overview 14
ExpressGraft – Antineoplastic 15
ExpressGraft – Antineoplastic Product Overview 15
ExpressGraft Antimicrobial – Diabetic Foot Ulcers 16
ExpressGraft Antimicrobial – Diabetic Foot Ulcers Product Overview 16
ExpressGraft Antimicrobial – Venous Leg Ulcers 17
ExpressGraft Antimicrobial – Venous Leg Ulcers Product Overview 17
ExpressGraft Pro-Angeogenic – Venous Leg Ulcers 18
ExpressGraft Pro-Angeogenic – Venous Leg Ulcers Product Overview 18
ExpressGraft Pro-Angiogenic – Diabetic Foot Ulcers 19
ExpressGraft Pro-Angiogenic – Diabetic Foot Ulcers Product Overview 19
ExpressGraft Skin Tissue 20
ExpressGraft Skin Tissue Product Overview 20
StrataGraft 21
StrataGraft Product Overview 21
StrataGraft Clinical Trial 22
Stratatech Corporation – Key Competitors 23
Stratatech Corporation – Key Employees 24
Stratatech Corporation – Locations And Subsidiaries 25
Head Office 25
Recent Developments 26
Stratatech Corporation, Recent Developments 26
Jul 31, 2013: Stratatech Awarded BARDA Contract Valued up to $47.2 Million for Advanced Development of StrataGraft Skin Tissue for Thermal Burns 26
Jan 16, 2013: Stratatech Announces Impressive Clinical Results For StrataGraft Skin Tissue 26
Jun 13, 2012: Stratatech’s StrataGraft Skin Substitute Receives FDA Orphan Drug Designation 27
Apr 27, 2012: Stratatech Reports Positive Interim Clinical Results For StrataGraft Skin Substitute 28
Sep 23, 2011: Stratatech Initiates Second Clinical Trial Of StrataGraft Skin Substitute 28
Dec 13, 2010: Stratatech Appoints Russell Smestad As president 28
Nov 16, 2010: Stratatech Receives $3.5 Million To Continue Development Of ExpressGraftEnhance Tissue 29
Jan 11, 2010: Stratatech To Collaborate With Fortune 200 Company On Product Development 29
Oct 01, 2009: Stratatech Receives $1.7 Million Grant To Develop New Product For Skin Cancer Treatment 29
Feb 03, 2009: Stratatech Genetically Modifies StrataGraft To Fight Against Potent Bacterial Infections 30
Appendix 31
Methodology 31
About GlobalData 31
Contact Us 31
Disclaimer 31

List of Tables
Stratatech Corporation, Key Facts 5
Stratatech Corporation Pipeline Products and Clinical Trials Overview 6
Stratatech Corporation Pipeline Products by Equipment Type 6
Stratatech Corporation Pipeline Products by Indication 7
Stratatech Corporation Clinical Trials by Trial Status 7
Stratatech Corporation, Key Facts 8
Stratatech Corporation, Major Products and Services 9
Stratatech Corporation Number of Pipeline Products by Development Stage 10
Stratatech Corporation Pipeline Products Summary by Development Stage 11
Stratatech Corporation Clinical Trials by Trial Status 12
Stratatech Corporation Clinical Trials Summary 13
EpiReady - Product Status 14
EpiReady - Product Description 14
ExpressGraft - Antineoplastic - Product Status 15
ExpressGraft - Antineoplastic - Product Description 15
ExpressGraft Antimicrobial - Diabetic Foot Ulcers - Product Status 16
ExpressGraft Antimicrobial - Diabetic Foot Ulcers - Product Description 16
ExpressGraft Antimicrobial - Venous Leg Ulcers - Product Status 17
ExpressGraft Antimicrobial - Venous Leg Ulcers - Product Description 17
ExpressGraft Pro-Angeogenic - Venous Leg Ulcers - Product Status 18
ExpressGraft Pro-Angeogenic - Venous Leg Ulcers - Product Description 18
ExpressGraft Pro-Angiogenic - Diabetic Foot Ulcers - Product Status 19
ExpressGraft Pro-Angiogenic - Diabetic Foot Ulcers - Product Description 19
ExpressGraft Skin Tissue - Product Status 20
ExpressGraft Skin Tissue - Product Description 20
StrataGraft - Product Status 21
StrataGraft - Product Description 21
StrataGraft - An Open-Label, Controlled, Randomized, Multicenter, Dose Escalation Study Evaluating the Safety and Efficacy of StrataGraft Skin Tissue in Promoting the Healing of the Deep Partial-Thickness Component of Complex Skin Defects as an Alternative to Autografting 22
Stratatech Corporation, Key Employees 24

List of Figures
Stratatech Corporation Pipeline Products by Equipment Type 6
Stratatech Corporation Pipeline Products by Development Stage 10
Stratatech Corporation Clinical Trials by Trial Status 12

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/


※おすすめ調査資料
※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
※当市場調査資料(GDME13426PD )"Stratatech Corporation:企業の製品パイプライン分析2014" (英文:Stratatech Corporation - Product Pipeline Analysis, 2014 Update)はGlobalData社が調査・発行しており、H&Iグローバルリサーチが販売します。


◆H&Iグローバルリサーチのお客様(例)◆


※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
※H&Iグローバルリサーチ(登録第5864124号)及びH&I(登録第5783645号)はH&Iグローバルリサーチ株式会社の商標です。